Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
May 23, 2024 09:50 ET
|
Apnimed, Inc.
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
December 21, 2023 08:30 ET
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
October 18, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
October 10, 2023 08:30 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
October 02, 2023 08:00 ET
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
September 21, 2023 05:30 ET
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
September 06, 2023 08:00 ET
|
Apnimed, Inc.
-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
APNIMED to Participate in Upcoming Investor Conferences in September
August 30, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
August 28, 2023 06:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...